<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742026</url>
  </required_header>
  <id_info>
    <org_study_id>GETH-PCRAGA</org_study_id>
    <nct_id>NCT01742026</nct_id>
  </id_info>
  <brief_title>Aspergillus PCR Early Detection in High Risk Oncohematological Patients</brief_title>
  <official_title>ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ADVANCE THERAPY ASPERGILLOSIS INVASIVE BY PCR DETECTION
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR
      EARLY DETECTION OF ASPERGILLUS
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of PCR technique for detection of Aspergillus DNA versus the standard technique for the determination of galactomannan Antigen (AGA) in serum</measure>
    <time_frame>18-20 months</time_frame>
    <description>To value the percentage of patients with likely/proven invasive fungal infection, diagnosed using only AGA tecnique or using AGA and PCR tecniques together.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">225</enrollment>
  <condition>Infections</condition>
  <arm_group>
    <arm_group_label>High Risk Oncohematological Patients</arm_group_label>
    <description>Detection Aspergillus PCR technique and Aspergillus AGA technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aspergillus PCR technique</intervention_name>
    <description>Aspergillus DNA PCR technique</description>
    <arm_group_label>High Risk Oncohematological Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aspergillus AGA technique</intervention_name>
    <description>Aspergillus AGA technique</description>
    <arm_group_label>High Risk Oncohematological Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of hematological patients at high risk of invasive fungal
        infection. Like: Leukemia acute mieloblasticas, myelodysplastic syndrome, patients with
        intensive chemotherapy and allogeneic hematopoietic transplantation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of informed consent to participate in the study.

          -  Adult patients (&gt; 18 years), diagnosed with acute myelogenous leukemia or
             myelodysplastic syndrome with chemotherapy (CT) intensive, or admitted to undergo
             allogeneic hematopoietic progenitor cells, or transplantation with graft versus host
             disease.

          -  The patient should be included in this protocol from the start of their chemotherapy
             or conditioning therapy as reflected in another section.

        Exclusion Criteria:

          -  Employment of antifungal prophylaxis (30 days prior to inclusion) with triazole /
             polyene with activity against Aspergillus (itraconazole, voriconazole, posaconazole,
             amphotericin B inhalation).

          -  Use of other systemic antifungal activity against Aspergillus (amphotericin,
             terbinafine, flucytosine, echinocandins, etc.). Therefore it will Fluconazole
             prophylaxis exclusively.

          -  Background of IFI proven / probable prior

          -  Probable IFI / tested at the time of inclusion in the study.

          -  Exclusion will cause a lack of compliance with the inclusion criteria.

          -  Patients who have a lack of follow biweekly with galactomannan or PCR. Have a
             bacterial infection not properly treated and controlled before starting empirical
             antifungal treatment (according to the definition given above). And finally they have
             a neutropenia of short duration that it creates a significant risk of IFI. This
             information will not be known logically to include the patient in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourdes Vazquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Ruiz, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d´Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rocio Parody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen del Rocio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat Rovira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat Batlle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Vallejo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Central de Asturias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosario Varela, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de A Coruña</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inmaculada Heras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Morales Meseguer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquin Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Solano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Teresa Olave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Gallardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Josep Trueta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High risk aspergillosis infection patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

